|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/12/19 Boston Scientific Corp 8-K:1,8,9 11/06/19 14:642K Shearman & Sterling LLP |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 41K 2: EX-1.1 Underwriting Agreement HTML 205K 3: EX-4.2 Form of 0.625% Senior Note Due 2027 HTML 67K 4: EX-5.1 Opinion Dated November 12, 2019 HTML 24K 5: EX-99.1 Press Release HTML 15K 10: R1 Cover HTML 48K 13: XML IDEA XML File -- Filing Summary XML 13K 9: XML XBRL Instance -- ss156905_8k_htm XML 15K 11: EXCEL IDEA Workbook of Financial Reports XLSX 6K 7: EX-101.LAB XBRL Labels -- bsx-20191106_lab XML 97K 8: EX-101.PRE XBRL Presentations -- bsx-20191106_pre XML 64K 6: EX-101.SCH XBRL Schema -- bsx-20191106 XSD 13K 14: JSON XBRL Instance as JSON Data -- MetaLinks 25± 33K 12: ZIP XBRL Zipped Folder -- 0000947871-19-000804-xbrl Zip 70K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): i November 6, 2019
i BOSTON SCIENTIFIC CORPORATION
(Exact name of registrant as specified in its charter)
| DELAWARE | i 1-11083 | i 04-2695240 | ||
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) | ||
| i 300 Boston Scientific Way, i Marlborough, i Massachusetts | i 01752-1234 | |||
| (Address of principal executive offices) | (Zip Code) | |||
Registrant’s telephone number, including area code: i (508) i 683-4000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| i ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| i ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| i ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| i ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
Trading Symbol |
Name of each exchange on which registered |
| i Common Stock, $0.01 par value per share | i BSX | i New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| C: |
ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT
On November 6, 2019, Boston Scientific Corporation (the “Company”) entered into an Underwriting Agreement, (as supplemented by the Terms Agreement, also dated November 6, 2019, the “Underwriting Agreement”), among the Company and Barclays Bank PLC, Merrill Lynch International and Goldman Sachs & Co. LLC, as representatives of the underwriters named in the Underwriting Agreement (the “Underwriters”), in connection with the Company’s previously announced pricing of €900,000,000 aggregate principal amount of senior notes. Pursuant to the Underwriting Agreement, the Underwriters agreed to purchase €900,000,000 in aggregate principal amount of the Company’s 0.625% Senior Notes due 2027 (the “Notes”) under the Company’s shelf registration statement on Form S-3 (File No. 333-223095). The Underwriting Agreement contains customary representations, warranties and agreements of the Company and customary conditions to closing, indemnification rights and obligations of the parties and termination provisions. The Underwriters and their affiliates have performed commercial banking, investment banking and advisory services for the Company from time to time for which they have received customary fees and expenses. The Underwriters and their affiliates may, from time to time, engage in transactions with and perform services for the Company in the ordinary course of their business.
The Notes were issued pursuant to an indenture dated as of May 29, 2013 between the Company and U.S. Bank National Association, as trustee (the “Indenture”). The Indenture contains covenants that restrict the Company’s ability, with certain exceptions, to (i) merge or consolidate with another entity or transfer all or substantially all of its property and assets, and (ii) incur liens. These covenants are subject to important exceptions and qualifications, as described in the Indenture. The Indenture also provides for customary events of default. Additional terms of the Notes are set forth in the form of notes attached hereto as Exhibit 4.2.
The foregoing descriptions of the Underwriting Agreement, the Indenture and the Notes are summaries and are qualified in their entirety by reference to such documents, which are attached as Exhibits 1.1, 4.1 and 4.2 to this Current Report on Form 8-K, respectively, and all of which are incorporated herein by reference.
ITEM 8.01 OTHER EVENTS
On November 12, 2019, the Company completed the offering of the Notes. The net proceeds from the offering of the Notes, after deducting the underwriting discount and estimated offering expenses, were approximately €887 million. The Company used the net proceeds from the offering of the Notes to (i) fund the previously announced tender offer for up to $1.0 billion in aggregate principal amount of certain series of the Company’s senior notes (the “Tender Offer”), and (ii) pay accrued and unpaid interest, premiums, fees and expenses in connection with the Tender Offer.
On November 12, 2019, the early settlement date of the Tender Offer, the Company completed the Tender Offer, pursuant to which it accepted $206,429,000, $566,455,000, and $227,117,000 of tendered principal amounts of its 4.125% Senior Notes due 2023, 4.000% Senior Notes due 2028 and 3.850% Senior Notes due 2025, respectively.
In connection with the offering of the Notes, the Company is filing a legal opinion regarding the validity of the Notes, attached as Exhibit 5.1 to this Current Report on Form 8-K.
Additionally, on November 12, 2019, the Company issued a press release pertaining to the events described in this Current Report on Form 8-K, a copy of which is attached as Exhibit 99.1 hereto and is hereby incorporated by reference herein.
C:
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits
* Documents filed or furnished with this report.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| BOSTON SCIENTIFIC CORPORATION | ||||||
| Date: November 12, 2019 | By: |
/s/ Vance R. Brown | ||||
|
Vice President and Chief Corporate Counsel | ||||||
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 11/12/19 | 4, 8-A12B | ||
| For Period end: | 11/6/19 | 424B5, FWP | ||
| 5/29/13 | 4, 8-K, S-3ASR, S-8 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/20/24 Boston Scientific Corp. 10-K 12/31/23 90:16M 2/23/23 Boston Scientific Corp. 10-K 12/31/22 102:22M 2/23/22 Boston Scientific Corp. S-3ASR 2/23/22 7:1.4M Toppan Merrill/FA 2/23/22 Boston Scientific Corp. 10-K 12/31/21 89:21M 2/23/21 Boston Scientific Corp. 10-K 12/31/20 87:20M |